MiR-219-5p Inhibits the Growth and Metastasis of Malignant Melanoma by Targeting BCL-2

Jianwen Long,1,2,3 Qiqige Menggen,4 Qimige Wuren,4 Quan Shi,2,3 and Xianming Pi2,3

1Department of Dermatology, The First Clinical Medicine School, Hubei University of Chinese Medicine, Wuhan, China
2Department of Dermatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China
3Department of Dermatology, Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, China
4Department of Dermatology, Mongolian Medicine Hospital, Bortala Mongol Autonomous Prefecture, China

Correspondence should be addressed to Jianwen Long; longjianwen@hbhtcm.com

Received 24 May 2017; Accepted 11 July 2017; Published 13 August 2017

1. Introduction

Malignant melanoma developing from melanocytes has shown significantly clinicopathological characteristics of high invasion, high metastasis, and high mortality [1, 2]. Although remarkable advances have been achieved in the treatment of tumors recently [3], the prognosis of metastatic melanoma remains still unsatisfied [4]. The etiology of melanoma is very complicated, involving cell differentiation, cell proliferation, cell apoptosis, and so on [5]. With the development of bioinformatics, new molecular targets have been discovered and implemented at the diagnosis and treatment of tumors [6].

MicroRNAs (miRNAs) are a kind of small 15–22-nucleotide noncoding RNA [7]. Many researches point out that miRNA is correlated with tumor growth and metastasis via acting as protumor or antitumor factors in a few neoplasms [8]. Meanwhile, some miRNAs are helpful to the occurrence, development, growth, metastasis, and chemotherapy resistance of melanoma through binding to the targeting mRNA [9–11]. Abnormal expression of miR-219-5p has been ascertained in some malignant tumors, and miR-219-5p has been identified to exert tumor suppressor function in a procession of different tumors [12, 13]. The expression and function of miR-219-5p have not been elucidated in melanoma up to date. The research aims to determine miR 219-5p level and investigate the specific effect of miR-219-5p on the development of melanoma.

2. Materials and Methods

2.1. Patients and Melanoma Samples. 42 of melanoma tissues and 20 nevi tissues were acquired from the Hubei provincial hospital of Traditional Chinese Medicine by resection and were stored in liquid nitrogen. Patients did not receive chemotherapy or radiation therapy before resection. This research was approved by the ethical committee of the Hubei Provincial Hospital of Traditional Chinese Medicine, and written informed consent was obtained from individuals with melanoma. These clinical features of the individuals with melanoma are represented in Table 1.

2.2. Cell Line and Reagents. A375, WM35, SK-MEL-5, and SK-MEL-2 cell lines were obtained from cell bank of Wuhan university and incubated in DMEM added with 10% fetal...
bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco, USA) in an atmosphere of 5% CO2 at 37°C. Human epidermal melanocytes (HEMa-LP) were gained from Cascade biologists, UK, and were incubated in HMGS-2 medium in the same condition as described in melanoma cell lines.

2.3. Plasmid Transfection. MiR-219-5p mimics and miR-control and pcDNA3.1 vector encoding Bcl-2 were obtained from GeneCopoeia. Transfection was applied with Lipofectamine 2000 reagent (Invitrogen) on the basis of the protocol description.

2.4. Qualitative RT-PCR. Total RNA was extracted from tissues and cells through the TRIzol reagent (Invitrogen) on the basis of the protocol kit protocol. The cDNA was synthesized and amplified using the TaqMan miRNA reverse transcription kit. The mRNA levels of miR-219-5p and U6 were determined by qRT-PCR using TaqMan human miRNA assay kit. The 2−ΔΔCT method was utilized to measure the relative fold difference, MiR-219-5p: (F) 5'-ACACTCCAG-CTGGGTGATTGTCCAAACGCAAT-3' and (R) 5'-CTC-AACTGGTGTCGTGGA-3', U6: (F) 5'-CTCGCTTCGGCA- GCACA-3' and (R) 5'-AACGCTTCACGAATTTGCGT-3'.

2.5. CCK-8 Assay. Melanoma cells proliferation activity was detected by CCK-8 assay according to the protocol's instruction. A375 cells after transfection are cultured in 96-well plates with the same conditions. At 12, 24, 48, and 72 h, 90 μl fresh culture media and 10 μl CCK-8 solutions were added to each sample. Subsequently, transacted melanoma cell was incubated at 37°C for 2 h, and the value was examined by a microplate reader at 450 nanometers.

2.6. Analysis of Apoptosis. At 48 hours after transfection, 2 × 10^5 A375 cells were cultured in six-well plates. The cells were washed and resuspended in buffer. The cell apoptosis was detected by flow cytometric assay with Annexin V-FITC and PI staining.

2.7. Transwell Chamber Assay. A375 cells were cultured for 48 h after transfection. Transwell assay was applied to determine the cell invasion activity. Transwell chamber membrane was coated with Matrigel. 2 × 10^5 cells were added in the upside chambers with serum-free medium. DMEM with 10% FBS was put into the downside chamber. After incubating for 48 h, swabs were utilized to wipe off the cells in the upside chamber; cells in the downside chamber were fixed and stained with 0.5% crystal violet. Cells count was performed using a microscope.

2.8. Wound Healing Assay. Cells after transfection were cultured in appropriate condition for 48 hours. Wounds were created by plastic scriber on the cell monolayer. Cells were then washed and incubated in DMEM with 10% FBS for 48 h. The migration activity was recorded using a microscope at 0 and 48 h and determined by subtracting the final wound width from the initial wound width.

2.9. Western Blot Assay. Cells were lysed, protease inhibitors were added to the lysates and cell lysate was centrifuged at 12000 Rpm at 4°C. The protein concentration was examined by the BCA kit (Pierce, USA). The protein was separated using 10% SDS-PAGE assay and moved to a PVDF membrane. Antibodies listed below were applied to determine the protein expression: Bcl-2 (1:500, Santa Cruz, USA), cleaved caspase 3 (1:500, Abcam, USA), and cleaved caspase 9 (1:500, Abcam, USA). Anti-β-actin (1:2000, Sigma-Aldrich, USA). Horseradish peroxidase-conjugated secondary antibody (1:1000, Abcam, USA). An ECL chemiluminescent kit (Millipore, USA) was applied to measure the bands.

2.10. Luciferase Reporter Assay. The 3’-UTR sequence of Bcl-2 or the mutated sequence was cloned into pMIR-REPORT vectors. 50 nM miR-219-5p mimics or corresponding control was transfected together with a reporter plasmid and 1 ng pRL-SV40 (Promega, USA) into the A375 cells. After 48 h, the active Luciferase level was determined by a Luciferase Reporter Assay (Promega, USA).
2.11. Chemosensitivity Assay. 48 h after transfection, A375 cells were incubated in fresh medium and then added to 96-well plates. Various doses of cisplatin or 5-FU were added to the cell culture for 72 h. Next, CCK-8 assay was applied to detect the cell survival.

2.12. Tumor Growth In Vivo. After transfection, A375 cells were transplanted into nude mice (25–30 g, six-week-old, n = 6), mice were sacrificed on 5 d, 10 d, 15 d, 20 d, and 25 d, and the weight and volume of tumors were measured and recorded.

2.13. Statistical Analysis. The SPSS 15.0 was applied for statistical analyses, including t-test, one-way analysis of variance, Fisher exact probability test, the Kaplan-Meier plot, and Pearson correlation analyses. All of the results were recorded as mean ± standard deviation. P < 0.05 was believed as statistically significant.

3. Results

3.1. MiR-219-5p Is Downregulated in Melanoma and Correlated with Unfavorable Prognosis in Individuals with Malignant Melanoma. The miR-219-5p levels in 42 of melanoma tissues and 20 of benign nevi tissues were investigated using qRT-PCR. Our results manifested that the miR-219-5p levels were obviously decreased in melanoma samples in comparison with benign nevi tissues (Figure 1(a)). The miR-219-5p levels in A375 cells, WM35 cells, SK-MEL-2 cells, and SK-MEL-5 cells were distinctly downregulated compared with HEMa-LP cells (Figure 1(b)). Patients with melanoma were divided into high miR-219-5p expression group (n = 21) and low miR-219-5p expression group (n = 21) according to the miR-219-5p average level. The correlation between the miR-219-5p expression and the clinical features of individuals with melanoma was investigated. There was no obvious correlation between the age and sex of patients and miR-219-5p expression, but the low expression of miR-219-5p was distinctly related to the TNM stage and distant migration of malignant melanoma as described as Table 1. Besides, low miR-219-5p level was correlated with decreased overall survival (Figure 1(c)). The results manifested that downregulation of miR-219-5p was closely correlated with the progression of melanoma. The transfection of miR-219-5p elevated the level of miR-219-5p in A375 cells and inhibited the proliferation of A375 cells, but the cotransfection of Bcl-2 weakened the inhibition function induced by miR-219-5p in A375 cells (Figures 1(d) and 1(e)).
3.2. Upregulation of miR-219-5p Inhibited A375 Cells Proliferation and Enhanced Apoptosis of A375 Cells. A375 cells transfected with miR-219-5p were subjected to proliferation assay and flow cytometric analysis. The results as illustrated in Figure 2 confirmed that high expression of miR-219-5p suppressed the A375 cells growth and promoted cell apoptosis; however, the cotransfection of Bcl-2 inversely partially the proliferation and apoptosis of A375 cells induced by miR-219-5p. Subsequently, we detected the protein expression related to apoptosis; indeed, the decreased level of Bcl-2 and the increased level of cleaved caspase 3 and cleaved caspase 9 were identified in miR-219-5p group compared with miR-control group. However, the effect of miR-219-5p on A375 cells was inhibited by the cotransfection of Bcl-2.

3.3. Upregulation of miR-219-5p Inhibited the Invasion and Migration of A375 Cells. Metastasis is the important causation of death associated with malignant melanoma; transwell assay and wound healing assay were performed to determine the influence of miR-219-5p on A375 cells metastasis (Figure 3). Ectopic expression of miR-219-5p obviously inhibited the metastasis of A375 cells. But the cotransfection of Bcl-2 weakened the function of miR-219-5p on A375 cells.

3.4. BCL-2 mRNA Was Confirmed as a Binding Target of miR-219-5p. Two important databases TargetScan 7.0 and miRanda were used for searching for the underlying downstream targets of miR-219-5p in melanoma cells. Bcl-2 was considered as a possible target for further study. The Luciferase Reporter analysis identified that 3-UTR of Bcl-2 was a downstream binding target of miR-219-5p as illustrated as Figure 4(a). The results manifested miR-219-5p obviously inhibited Luciferase activity in wild type but did not affect that in mutated type (Figure 4(b)).

3.5. miR-219-5p Inhibited Melanoma Growth in an Animal Experiment and Enhanced Chemosensitivity in A375 Cells. The role of miR-219-5p in melanoma was identified in nude mice models. The volume of tumors was obviously reduced in the miR-219-5p mimics group in comparison with those in the miR-control group (Figure 4(d)). The final weight of
Figure 3: Upregulation of miR-219-5p suppressed A375 cells metastasis. Note. (a) Upregulation of miR-219-5p distinctly inhibited the A375 cells metastasis. (b) The cotransfection of Bcl-2 obviously alleviated the inhibition of miR-219-5p in A375 cells metastasis. *P < 0.05, compared with miR-control group. #P < 0.05, compared with miR-219-5p group.

4. Discussion

Tumor development is a complicated evolution and regulated by protumor and antitumor elements [14]. More and more researches have identified that microRNAs exert important function in tumorigenesis via modulating the targeting gene expression, including cell proliferation, differentiation, apoptosis, and metastasis [15, 16]. MiR-219-5p has been confirmed to be expressed abnormally and play antitumor roles in a few tumors. For example, miR-219-5p inhibited the growth and metastasis of gastric cancer cells via targeting LRH-1 [17], and miR-219-5p exerted an antitumor function in colon cancer via binding to Sall4 [12]; however, the expression and effect of miR-219-5p in melanoma still remained unclear. In this article, the miR-219-5p level in melanoma tissues and cell lines was found to be downregulated. The low miR-219-5p level was obviously related to the malignant clinical features of patients with melanoma. Furtherly, it was identified that miR-219-5p suppressed the A375 cells proliferation and metastasis and promoted A375 cells apoptosis. Ectopic expression of miR-219-5p inhibited melanoma growth in vivo. These data demonstrated that miR-219-5p exerted a tumor suppressor function in melanoma. To investigate the peculiar regulatory mechanism of miR-219-5p on the development of melanoma, we retrieved two important databases, TargetScan 7.0 and miRanda, and found Bcl-2 may be an important downstream targeting gene, and we confirmed that the Bcl-2 protein level was significantly inversely correlated with the miR-219-5p level in tumor tissues. Furthermore, the Luciferase Reporter analysis revealed BCL-2 mRNA was exactly a binding target of miR-219-5p.

Bcl-2 gene, an important antiapoptotic gene, influences the intrinsic apoptosis pathway [18, 19]. Meanwhile, Bcl-2 can promote tumor invasion and metastasis [20]. Inhibition of
Figure 4: BCL-2 was a functional targeting mRNA of miR-219-5p on A375 cells. Note. (a) miR-219-5p and its predicted binding sequence for WT in BCL-2. (b) MiR-219-5p decreased Luciferase Reporter activities of Bcl-2 in wild type but had no significant impact on that of Bcl-2 in mutated type. (c) The transfection of miR-219-5p decreased the tumor volume. (d) The transfection of miR-219-5p reduced the tumor weight. (e and f) The transfection of miR-219-5p reinforced chemosensitivity to cisplatin or 5-FU treatment in A375 cells, but cotransfection of Bcl-2 weakened the function of miR-219-5p on A375 cell proliferation. \(* P < 0.05\), compared with miR-control.

Bcl-2 expression has been believed as an important treatment strategy for various cancers [21]. The following assays identified that the Bcl-2 level was significantly reduced, and the cleaved caspase 3 and 9 level were elevated in miR-219-5p group compared with the control group. Cotransfection of Bcl-2 recovered partially the proliferation and metastasis function of A375 cells inhibited by miR-219-5p and suppressed the apoptosis of A375 cells. These results showed that the impact of miR-219-5p on melanoma development was made by in part targeting the Bcl-2 mRNA.

In briefly, the research confirms that miR-219-5p exerts an antitumor function via partially regulating the Bcl-2 protein expression. The mediation of miR-219-5p may be a new and crucial scheme for molecular treatment of melanoma.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] T. Achkar and A. A. Tarhini, “The use of immunotherapy in the treatment of melanoma,” Journal of hematolgy oncology, vol. 10, no. 1, p. 88, 2017.

[2] A. A. Tarhini, “Immunotherapy of melanoma,” Current Molecular Pharmacology, vol. 9, no. 3, pp. 196–207, 2016.

[3] D. Davar, A. A. Tarhini, and J. M. Kirkwood, "Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach," Clinics in Dermatology, vol. 31, no. 3, pp. 237–250, 2013.

[4] A. J. Olszanski, "Current and future roles of targeted therapy and immunotherapy in advanced melanoma," Journal of Managed Care Pharmacy, vol. 20, no. 4, pp. 346–356, 2014.

[5] K. S. Hoek, "Melanoma progression, gene expression and DNA microarrays," Ital Dermatol Venereol, vol. 144, no. 1, pp. 39–49, 2009.

[6] E. Hulstaert, L. Brochez, P. Volders, J. Vandesompele, and P. Mestdagh, "Long non-coding RNAs in cutaneous melanoma: clinical perspectives," Oncotarget, 2017.

[7] Y. Tutar, "miRNA and cancer; computational and experimental approaches," Current Pharmaceutical Biotechnology, vol. 15, no. 5, p. 429, 2014.

[8] B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, "microRNAs as oncogenes and tumor suppressors," Developmental Biology, vol. 362, no. 1, pp. 1–12, 2007.

[9] H. Wang, "Predicting cancer-related MiRNAs using expression profiles in tumor tissue," Current Pharmaceutical Biotechnology, vol. 15, no. 5, pp. 438–444, 2014.
[10] N. Lynam-Lennon, S. G. Maher, and J. V. Reynolds, “The roles of microRNA in cancer and apoptosis,” Biological Reviews, vol. 84, no. 1, pp. 55–71, 2009.

[11] M. N. Aftab, M. E. Dinger, and R. J. Perera, “The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma,” Archives of Biochemistry and Biophysics, vol. 563, pp. 60–70, 2014.

[12] J. Cheng, R. Deng, P. Zhang et al., “MIR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4,” Oncology Reports, vol. 34, no. 4, pp. 1923–1932, 2015.

[13] K.-B. Song, W.-J. Liu, and S.-S. Jia, “MiR-219 inhibits the growth and metastasis of TSCC cells by targeting PRKCI,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 9, pp. 2957–2965, 2014.

[14] N. McGranahan and C. Swanton, “Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future,” Cell, vol. 168, no. 4, pp. 613–628, 2017.

[15] M. Klingenberg, A. Matsuda, S. Diederichs, and T. Patel, “Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets,” Journal of Hepatology, 2017.

[16] H. Sha, D. Wang, D. Chen et al., “MiR-138: A promising therapeutic target for cancer,” Tumor Biology, vol. 39, no. 4, Article ID 101042831769757, 2017.

[17] C. Li, J. Dong, Z. Han, and K. Zhang, “MicroRNA-219-5p Represses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Targeting the LRH-1/Wnt/β-Catenin Signaling Pathway,” Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, vol. 25, no. 4, pp. 617–627, 2017.

[18] S. W. Lowe, E. Cepero, and G. Evan, “Intrinsic tumour suppression,” Nature, vol. 432, no. 7015, pp. 307–315, 2004.

[19] R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008.

[20] J. Choi, K. Choi, E. N. Benveniste et al., “Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2,” Cancer Research, vol. 65, no. 13, pp. 5554–5560, 2005.

[21] M. H. Kang and C. P. Reynolds, “Bcl-2 Inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy,” Clinical Cancer Research, vol. 15, no. 4, pp. 1126–1132, 2009.